Tan Ince, MD, PhD

Highlights

1
NPJ breast cancer · 2022
LMLuigi Marchionni TITan Ince
PMID: 36038558PMCID: PMC9424319DOISenior author8 citations
2
Breast cancer research : BCR · 2024
RTRulla Tamimi LMLuigi Marchionni TITan Ince
PMID: 39272208PMCID: PMC11395215DOISenior author3 citations
3
Cancers · 2023
MCMassimo Cristofanilli TITan Ince
PMID: 36672285PMCID: PMC9856736DOISenior author11 citations

81

1 grant

PI
Culture of tumor versus normal cells
National Cancer Institute · 2024–2028
R01CA285335-03

Completed grants (9)

Sub-PI
The role of type 2 inflammation in the initiation and progression of metaplastic differentiation and neoplastic transformation of gastric epithelia
National Cancer Institute · 2020–2025 · via University of Miami
R01CA245673-05
MPI
NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
National Cancer Institute · 2022–2025 · via NRG Oncology
U10CA180868-11
PI
Live Tumor Culture Core and Tissue Specific Culture System for Human Cancers
National Cancer Institute · 2020–2024
R33CA214310-03
PI
Isolation and Characterization of Metastatic Breast Cancer Cell-of-Origin
Breast Cancer Research Foundation · 2021–2023
BCRF-21-188-02
PI
SRA: TumorGenesis, Inc - A Wholly Owned Subsidiary of Predictive Oncology, Inc (NASDAQ: POAI)
Predictive Oncology Inc. · 2021–2022Contract
PO 215256-01
PI
Isolation and Characterization of Metastatic Breast Cancer Cell-of-Origin
Breast Cancer Research Foundation · 2020–2021
BCRF 204266-01
PI
Computational and Biological Deconvolution of Epigenomic Datasets
NIEHS · 2014–2017 · via NIH RePORTER
R01ES024991-01
PI
Epigenomic Mapping in Human Tumor Stem Cells
NCI · 2009–2015 · via NIH RePORTER
R01CA146445-05
PI
Comparative phenotypic, functional, and molecular analysis of ESC and iPSC
NHLBI · 2009–2012 · via NIH RePORTER
RC2HL102815-02

2

GLG Pharma · United States Biological